Global Biopharmaceutical Company - Bristol Myers Squibb
The future of diversity in clinical trials
Meet some of the first cohort of diverse medical students dedicated to improving health equity who have been chosen to participate in the Robert A. Winn Clinical Investigator Pathway Program.
2022 Second Quarter Results >
Bristol Myers Squibb reports second quarter revenues of $11.9 Billion; GAAP EPS of $0.66 and non-GAAP EPS of $1.93 which include net impact of ($0.14) per share due to acquired IPRD charges and licensing income. Read more, including important cautionary statements about forward-looking information.
A subset of BMS.com, Life & Science Stories is our digital magazine where we share the work our global community of colleagues are doing around the world to help patients and advance scientific innovation.
Looking for Answers?
Quick links to helpful resources.